Does Trinity Industries, Inc. (NYSE:TRN) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend […] …read more […]
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons. Nevertheless, the data show elite investors’ consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat the S&P […] …read more […]
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and deteriorating expectations towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the second quarter and hedging or reducing many of […] …read more […]
European Central Bank President Mario Draghi defended his ultra-easy monetary policy stance on Thursday as his eight-year tenure at the bank closes in exactly the same place he started: trying to prop up a perpetually ailing currency bloc.
European Central Bank President Mario Draghi on Thursday praised Germany’s nominee for the executive board Isabel Schnabel as an excellent economist who would enhance discussions at the bank.
Cystic fibrosis patients in England will have access to life-extending drugs after the state-funded health service said it had agreed a pricing deal with manufacturer Vertex Pharmaceuticals. England’s National Health Service (NHS) has been negotiating with Vertex for years about supplying Orkambi, a combination drug that improves lung function. The U.S. company had wanted to charge around 100,000 pounds ($129,000) a year for a course of Orkambi, according to reports. …read more […]
Oil edged further above $61 a barrel on Thursday as a surprise drop in U.S. crude inventories and the prospect of further market-supporting action by OPEC and its allies offset concern over the outlook for demand.
Comcast Corp beat Wall Street profit and revenue estimates on Thursday, as the company added high-speed internet customers and lost more video subscribers than expected.
Do you want to build your wealth, but don’t know how to begin?
Wealth creation can seem like a tall order. When it’s hard enough to pay the bills, growing your nest egg can feel daunting. But plenty of people build their fortunes from humble beginnings.
Take John D. Rockefeller for example.
He got his first job as an assistant bookkeeper making only $16 a month. Today he is recognized as the most successful business tycoon in American history. You might not become the next Rockefeller, but you can take the right steps to build your wealth. You just need the right plan, …read more […]
New orders for key U.S.-made capital goods fell more than expected in September and shipments also declined, a sign that business investment remains weak amid the continuing fallout from the U.S.-China trade war but other data on Thursday showed it has yet to have much effect on the overall jobs market.
Tesla shocked Wall Street with its earnings report yesterday, revealing that the company has returned to profitability. Yahoo Finance’s Brian Sozzi and Alexis Christoforous break down the quarter with Garrett Nelson of CFRA. …read more […]
When you buy shares in a company, it’s worth keeping in mind the possibility that it could fail, and you could lose… …read more […]
Wall Street was on course to open higher on Thursday, as solid results from Microsoft, Lam Research and Tesla lifted sentiment following lackluster reports from big bellwether companies in the previous session.
American Airlines Group Inc trimmed its 2019 outlook on Thursday after raising the estimated costs related to the Boeing 737 MAX grounding to $540 million for the year, even after a quarterly profit increase that beat Wall Street estimates.
Cystic fibrosis patients in England will have access to life-extending drugs after the state-funded health service said it had agreed a pricing deal with manufacturer Vertex Pharmaceuticals. England’s National Health Service (NHS) has been negotiating with Vertex for years about supplying Orkambi, a combination drug that improves lung function. The U.S. company had wanted to charge around 100,000 pounds ($129,000) a year for a course of Orkambi, according to reports. …read more […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
